HomeClinical TopicsFDA approves new treatment for patients with hemophilia B

FDA approves new treatment for patients with hemophilia B

On March 4, the Food and Drug Administration (FDA) approved Idelvion, Coagulation Factor IX (Recombinant), Albumin Fusion Protein, for use in children and adults with Hemophilia B. Idelvion is the first coagulation factor-albumin fusion protein product to be approved. Read more

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Recent Content